do glp 1 affect bipolar disorder IUPHAR review – Glucagon-like peptide-1 (GLP-1) and substance use disorders: An emerging pharmacotherapeutic target Insights into a possible role

Oral Absorption Enhancement Patent Landscape: Competitors and Alternatives Pfizers danuglipron, a small-molecule GLP-1 receptor agonist (not a peptide), sidesteps the oral peptide delivery problem by using a molecule small enough to absorb conventionally

Start your intake The credentialing questions worth asking Hers is the women's brand of Hims & Hers Health, a publicly traded telehealth company, and it operates as subscription telehealth in the GLP-1 space

CART peptides are found areas of the brain involved in the control of feeding behaviors including regions of the hypothalamus such as the VMN, lateral hypothalamus (LH), PVN, NTS, ARC, and the nucleus accumbens

Similar trends were observed for both population subgroups with T2D or overweight/obesity

In many places, telehealth doctors and nurses are legally allowed to treat patients across state lines

Patient-specific factors that influence choice include: Concurrent diabetes : Patients with type 2 diabetes may have broader access through NHS prescribing pathways BMI and weight loss goals : Higher BMI patients may benefit from agents with greater weight loss efficacy Tolerability : Previous experience with gastrointestinal side effects may guide selection Injection preference : Some patients strongly prefer weekly over daily injections, or oral over injectable formulations Cardiovascular disease : Certain GLP-1 agonists have proven cardiovascular benefits, which may be relevant for high-risk patients Ultimately, the choice should be individualised through shared decision-making between patient and clinician, considering the available evidence, licensed indications, local prescribing policies, and patient preferences